Cargando…
Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome
INTRODUCTION: In autoimmune atypical hemolytic uremic syndrome (aHUS), the complement regulator factor H (FH) is blocked by FH autoantibodies, while 90% of the patients carry a homozygous deletion of its homolog complement FH-related protein 1 (CFHR1). The functional consequence of FH-blockade is wi...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371605/ https://www.ncbi.nlm.nih.gov/pubmed/28424685 http://dx.doi.org/10.3389/fimmu.2017.00302 |
_version_ | 1782518452635828224 |
---|---|
author | Trojnár, Eszter Józsi, Mihály Uray, Katalin Csuka, Dorottya Szilágyi, Ágnes Milosevic, Danko Stojanović, Vesna D. Spasojević, Brankica Rusai, Krisztina Müller, Thomas Arbeiter, Klaus Kelen, Kata Szabó, Attila J. Reusz, György S. Hyvärinen, Satu Jokiranta, T. Sakari Prohászka, Zoltán |
author_facet | Trojnár, Eszter Józsi, Mihály Uray, Katalin Csuka, Dorottya Szilágyi, Ágnes Milosevic, Danko Stojanović, Vesna D. Spasojević, Brankica Rusai, Krisztina Müller, Thomas Arbeiter, Klaus Kelen, Kata Szabó, Attila J. Reusz, György S. Hyvärinen, Satu Jokiranta, T. Sakari Prohászka, Zoltán |
author_sort | Trojnár, Eszter |
collection | PubMed |
description | INTRODUCTION: In autoimmune atypical hemolytic uremic syndrome (aHUS), the complement regulator factor H (FH) is blocked by FH autoantibodies, while 90% of the patients carry a homozygous deletion of its homolog complement FH-related protein 1 (CFHR1). The functional consequence of FH-blockade is widely established; however, the molecular basis of autoantibody binding and the role of CFHR1 deficiency in disease pathogenesis are still unknown. We performed epitope mapping of FH to provide structural insight in the autoantibody recruitment on FH and potentially CFHR1. METHODS: Eight anti-FH positive aHUS patients were enrolled in this study. With overlapping synthetic FH and CFHR1 peptides, we located the amino acids (aa) involved in binding of acute and convalescence stage autoantibodies. We confirmed the location of the mapped epitopes using recombinant FH domains 19–20 that carried single-aa substitutions at the suspected antibody binding sites in three of our patients. Location of the linear epitopes and the introduced point mutations was visualized using crystal structures of the corresponding domains of FH and CFHR1. RESULTS: We identified three linear epitopes on FH (aa1157–1171; aa1177–1191; and aa1207–1226) and one on CFHR1 (aa276–290) that are recognized both in the acute and convalescence stages of aHUS. We observed a similar extent of autoantibody binding to the aHUS-specific epitope aa1177–1191 on FH and aa276–290 on CFHR1, despite seven of our patients being deficient for CFHR1. Epitope mapping with the domain constructs validated the location of the linear epitopes on FH with a distinct autoantibody binding motif within aa1183–1198 in line with published observations. SUMMARY: According to the results, the linear epitopes we identified are located close to each other on the crystal structure of FH domains 19–20. This tertiary configuration contains the amino acids reported to be involved in C3b and sialic acid binding on the regulator, which may explain the functional deficiency of FH in the presence of autoantibodies. The data we provide identify the exact structures involved in autoantibody recruitment on FH and confirm the presence of an autoantibody binding epitope on CFHR1. |
format | Online Article Text |
id | pubmed-5371605 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53716052017-04-19 Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome Trojnár, Eszter Józsi, Mihály Uray, Katalin Csuka, Dorottya Szilágyi, Ágnes Milosevic, Danko Stojanović, Vesna D. Spasojević, Brankica Rusai, Krisztina Müller, Thomas Arbeiter, Klaus Kelen, Kata Szabó, Attila J. Reusz, György S. Hyvärinen, Satu Jokiranta, T. Sakari Prohászka, Zoltán Front Immunol Immunology INTRODUCTION: In autoimmune atypical hemolytic uremic syndrome (aHUS), the complement regulator factor H (FH) is blocked by FH autoantibodies, while 90% of the patients carry a homozygous deletion of its homolog complement FH-related protein 1 (CFHR1). The functional consequence of FH-blockade is widely established; however, the molecular basis of autoantibody binding and the role of CFHR1 deficiency in disease pathogenesis are still unknown. We performed epitope mapping of FH to provide structural insight in the autoantibody recruitment on FH and potentially CFHR1. METHODS: Eight anti-FH positive aHUS patients were enrolled in this study. With overlapping synthetic FH and CFHR1 peptides, we located the amino acids (aa) involved in binding of acute and convalescence stage autoantibodies. We confirmed the location of the mapped epitopes using recombinant FH domains 19–20 that carried single-aa substitutions at the suspected antibody binding sites in three of our patients. Location of the linear epitopes and the introduced point mutations was visualized using crystal structures of the corresponding domains of FH and CFHR1. RESULTS: We identified three linear epitopes on FH (aa1157–1171; aa1177–1191; and aa1207–1226) and one on CFHR1 (aa276–290) that are recognized both in the acute and convalescence stages of aHUS. We observed a similar extent of autoantibody binding to the aHUS-specific epitope aa1177–1191 on FH and aa276–290 on CFHR1, despite seven of our patients being deficient for CFHR1. Epitope mapping with the domain constructs validated the location of the linear epitopes on FH with a distinct autoantibody binding motif within aa1183–1198 in line with published observations. SUMMARY: According to the results, the linear epitopes we identified are located close to each other on the crystal structure of FH domains 19–20. This tertiary configuration contains the amino acids reported to be involved in C3b and sialic acid binding on the regulator, which may explain the functional deficiency of FH in the presence of autoantibodies. The data we provide identify the exact structures involved in autoantibody recruitment on FH and confirm the presence of an autoantibody binding epitope on CFHR1. Frontiers Media S.A. 2017-03-30 /pmc/articles/PMC5371605/ /pubmed/28424685 http://dx.doi.org/10.3389/fimmu.2017.00302 Text en Copyright © 2017 Trojnár, Józsi, Uray, Csuka, Szilágyi, Milosevic, Stojanović, Spasojević, Rusai, Müller, Arbeiter, Kelen, Szabó, Reusz, Hyvärinen, Jokiranta and Prohászka. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Trojnár, Eszter Józsi, Mihály Uray, Katalin Csuka, Dorottya Szilágyi, Ágnes Milosevic, Danko Stojanović, Vesna D. Spasojević, Brankica Rusai, Krisztina Müller, Thomas Arbeiter, Klaus Kelen, Kata Szabó, Attila J. Reusz, György S. Hyvärinen, Satu Jokiranta, T. Sakari Prohászka, Zoltán Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome |
title | Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome |
title_full | Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome |
title_fullStr | Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome |
title_full_unstemmed | Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome |
title_short | Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome |
title_sort | analysis of linear antibody epitopes on factor h and cfhr1 using sera of patients with autoimmune atypical hemolytic uremic syndrome |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371605/ https://www.ncbi.nlm.nih.gov/pubmed/28424685 http://dx.doi.org/10.3389/fimmu.2017.00302 |
work_keys_str_mv | AT trojnareszter analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT jozsimihaly analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT uraykatalin analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT csukadorottya analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT szilagyiagnes analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT milosevicdanko analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT stojanovicvesnad analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT spasojevicbrankica analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT rusaikrisztina analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT mullerthomas analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT arbeiterklaus analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT kelenkata analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT szaboattilaj analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT reuszgyorgys analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT hyvarinensatu analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT jokirantatsakari analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome AT prohaszkazoltan analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome |